Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
Nichols KK, Holland E, Toyos MM, et al. Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial. Clin Ophthalmol. 2018;12:263–270.On page 266, both mentions of Figure 3, should be Figure 4. On page 267, Figure 4 is drawn incorrec...
Guardado en:
Autores principales: | Nichols KK, Holland E, Toyos MM, Peace JH, Majmudar P, Raychaudhuri A, Hamdani M, Roy M, Shojaei A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a0522dfed8ed48989c87d173b448d181 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
por: Nichols KK, et al.
Publicado: (2018) -
Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez AL
Publicado: (2018) -
Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White DE, et al.
Publicado: (2019) -
Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease
por: Hovanesian JA, et al.
Publicado: (2021) -
Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin MR, et al.
Publicado: (2017)